Change in high-sensitivity C-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals

AIDS Research and Human Retroviruses

Volumn 27, Issue 5, 2011, Pages 461-468

  Shikuma, Cecilia M ^a   Ribaudo, Heather J ^b   Zheng, Yu ^b   Gulick, Roy M ^c   Meyer III, William A ^d   Tashima, Karen T ^e   Bastow, Barbara ^f   Kuritzkes, Daniel R ^g   Glesby, Marshall J ^c  

^a UNIVERSITY OF HAWAII   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e BROWN UNIVERSITY   (United States)

^f SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; C REACTIVE PROTEIN; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LACTIC ACID; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; C-REACTIVE PROTEIN; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SEX FACTORS;

EID: 79955767684     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0154     Document Type: Article

References (32)

1. Danesh J, Whincup P, Walker M, et al.: Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000;321(7255):199-204. (Pubitemid 30459555)
2. Lau B, Sharrett AR, Kingsley LA, et al.: C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006;166(1):64-70. (Pubitemid 43063843)
3. Feldman JG, Goldwasser P, Holman S, DeHovitz J, and Minkoff H: C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr 2003;32(2):210-214. (Pubitemid 36222724)
4. Henry K, Kitch D, Dube M, et al.: C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS 2004;18(18):2434-2437. (Pubitemid 40065914)
5. Sabin CA, Worm SW, Weber R, et al.: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008;371(9622): 1417-1426.
6. Worm SW, Sabin C, Weber R, et al.: Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis Feb1 2010:201(3):318-330.
7. DAD Study Groups: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22(14):F17-24.
8. Cooper D, Bloch M, Humphries A, Amin J, Baker D, Emery S, and Carr A for the STEAL Study Investigators: Simplification with Fixed-dose Tenofovir/Emtricitabine or Abacavir/ Lamivudine in Adults with Suppressed HIV Replication: The STEAL Study, a Randomized, Open-label, 96-Week, Non-inferiority Trial. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009. Abstract 576.
9. Brothers CH, Hernandez JE, Cutrell AG, et al.: Risk of myocardial infarction and abacavir therapy: No increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009;51(1): 20-28.
10. Lang S, Mary-Krause M, Cotte L, et al.: Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a casecontrol study nested within the French Hospital Database on HIV ANRS cohort C04. Arch Infern Med Jul 26 2010; 170(14):1228-1238.
11. Lichtenstein K, Buckner K, Armon C, Tedaldi E, Chmiel J, Wood K, et al.: Low CD4 Count is an Important Risk Factor for Cardiovascular Disease in the US HIV Outpatient Study (HOPS). 17th IAC 2008: Poster THPE0236, 2008.
12. Gulick RM, Ribaudo HJ, Shikuma CM, et al.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350(18):1850-1861. (Pubitemid 38917251)
13. Shikuma CM, Yang Y, Glesby MJ, Meyer WA, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, and Gulick RM for the AIDS Clinical Trials Group Protocol A5095 Study Team: Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study-A5095). J Acquir Immune Defic Syndr 2007; 44(5): 540-550. (Pubitemid 46594897)
14. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107(3):499-511. (Pubitemid 36158056)
15. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, and Kremastinos DT: Inflammatory and non-invasive vascular markers: The multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 2008; 199(1):3-11.
16. Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350(14):1387-1397. (Pubitemid 38419992)
17. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352(1):20-28. (Pubitemid 40075677)
18. Ridker PM and Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004;109(16):1955-1959. (Pubitemid 38544485)
19. Ridker PM, Buring JE, Cook NR, and Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107(3): 391-397.
20. Reingold J, Wanke C, Kotler D, et al.: Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: The fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008;48(2):142-148.
21. Triant VA, Meigs JB, and Grinspoon SK: Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009;51(3):268-273.
22. Drain PK, Kupka R, Msamanga GI, Urassa W, Mugusi F, and Fawzi WW: C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS 2007;21(15):2067-2075. (Pubitemid 47462156)
23. McComsey GA Smith KY, Patel P, Bellos NC, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Yau L, and Shaefer MS: Similar Reductions in Markers of Inflammation and Endothelial Activation after Initiation of Abacavir/ Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/ FTC) in the HEAT Study. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.
24. Calabro P, Chang DW, Willerson JT, and Yeh ET: Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: Linking obesity to vascular inflammation. J Am Coll Cardiol 2005;46(6):1112-1113. (Pubitemid 41316523)
25. Calabro P, Willerson JT, and Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003;108(16): 1930-1932. (Pubitemid 37296536)
26. Kushner I, Rzewnicki D, and Samols D: What does minor elevation of C-reactive protein signify? Am J Med 2006; 119(2):166 e17-28.
27. Saltevo J, Vanhala M, Kautiainen H, Kumpusalo E, and Laakso M: Gender differences in C-reactive protein, interleukin- 1 receptor antagonist and adiponectin levels in the metabolic syndrome: A population-based study. Diabet Med 2008;25(6):747-750. (Pubitemid 351782826)
28. Buchbinder S, Kratzsch J, Fiedler GM, et al.: Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest 2008;68(2):140-144. (Pubitemid 351481731)
29. Cauci S, Di Santolo M, Culhane JF, Stel G, Gonano F, and Guaschino S: Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol 2008;111(4):857-864. (Pubitemid 351482617)
30. Dolan SE, Hadigan C, Killilea KM, et al.: Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005;39(1):44-54. (Pubitemid 40617018)
31. Masia M, Bernal E, Padilla S, et al.: The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 2007;195(1):167-171. (Pubitemid 47569983)
32. Boger MS, Shintani A, Redhage LA, et al.: Highly sensitive C-reactive protein, body mass index, and serum lipids in HIVinfected persons receiving antiretroviral therapy: A longitudinal study. J Acquir Immune Defic Syndr 2009;52(4):480-487.